Prima Biomed Ltd (NASDAQ:PBMD, AX:PRR) has progressed to the final stage of dose selection for its Phase IIb trial of IMP321 in breast cancer, and is on track to commence randomisation in Q416. IMP321 is a soluble LAG-3 fusion protein that doubled tumour response rates in Phase IIa.
Separately, partner Novartis has expanded its Phase I LAG-3 programme in solid tumours and GSK plans to move its partnered programme in autoimmune disease into Phase II this year. With the company’s development of in-house and partnered LAG-3 programmes on track, our valuation increases slightly to A$282m (14c/share).
First cohort in AIPAC safely treated
The first six patients have safely completed treatment in the AIPAC Phase IIb trial of IMP321 in breast cancer. No drug-related serious adverse events were observed and data demonstrated activation of blood monocytes/dendritic cells and CD8 T-cells.
Recruitment is underway in the second cohort of nine patients who will receive 30mg of IMP321 in combination with paclitaxel, compared to 6mg in the first cohort. Results for both cohorts are expected in Q416; the trial will then move to the randomisation phase in 196 patients.
To read the entire report Please click on the pdf File Below